CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to ...

Crinetics (CRNX) announced the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, a multicenter, randomized, double-blind, ...

Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent ...

Please provide your email address to receive an email when new articles are posted on . A 65-year-old woman with a history of type 2 diabetes, coronary artery disease with congestive heart failure and ...

1 Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, NY, 2 Department of Medicine, New York Medical College, New York, NY A 61-year-old African American woman with a history of ...

WE recently recognized distinctive ophthalmic consequences of the carcinoid syndrome that have not been reported. Patients with malignant carcinoid were studied during their hospital courses at the ...

(BPT) - Ten years ago, Hollywood actress and producer Christina Simpkins was going about her regular activities – eating a healthy diet, writing, making films and practicing yoga. Then, Christina ...

Shubham Pant, MD: The first thing people say when people hear “tumor” is, “Oh my God, I’m going to die, this is a tumor.” But tell me, as a doctor who treats neuroendocrine tumors, there can be ...

A carcinoid tumor is a type of cancer that develops in different parts of the body and is characterized by a slow growth phase. Credit: Photomicrograph of a carcinoid tumor. Credit: David ...

A 66-year-old woman was first admitted to the Mayo Clinic on April 13, 1962, because of a mass in the neck that she had noted accidentally 2 months previously. She had had no significant symptoms, and ...

SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) ...